aprevo® Personalized Interbody

About Carlsmed

Carlsmed's mission is to improve patient outcomes and decrease the cost of healthcare in spine surgery by shifting from standard implants to a fully personalized approach. The company has achieved significant commercial traction with its FDA-cleared aprevo® platform, reporting $50.5 million in revenue for FY 2025, representing 86% year-over-year growth. Its strategy centers on expanding its personalized implant portfolio, generating robust clinical evidence, and leveraging its integrated digital platform to drive adoption in the large and growing spine surgery market.

About Carlsmed

Carlsmed's mission is to improve patient outcomes and decrease the cost of healthcare in spine surgery by shifting from standard implants to a fully personalized approach. The company has achieved significant commercial traction with its FDA-cleared aprevo® platform, reporting $50.5 million in revenue for FY 2025, representing 86% year-over-year growth. Its strategy centers on expanding its personalized implant portfolio, generating robust clinical evidence, and leveraging its integrated digital platform to drive adoption in the large and growing spine surgery market.

Therapeutic Areas

Other Lumbar Interbody Fusion Drugs